Characteristics and outcomes of medulloblastoma in adults

Ang, Celina; Hauerstock, David; Guiot, Marie‐Christine; Kasymjanova, G.; Roberge, David; Kavan, Petr; Muanza, Thierry

doi:10.1002/pbc.21588

Cited by 46 publications

(26 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some investigators postulate that maturity of language and motor systems in older individuals makes them less vulnerable (21,(32)(33)(34). Differential tumor location in older groups may be a confounding factor (35)(36)(37)(38).…”

Section: Discussionmentioning

confidence: 96%

Incidence, Risks, and Sequelae of Posterior Fossa Syndrome in Pediatric Medulloblastoma

Korah

Esiashvili

Mazewski

et al. 2010

International Journal of Radiation Oncology*Biology*Physics

111

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 96%

Incidence, Risks, and Sequelae of Posterior Fossa Syndrome in Pediatric Medulloblastoma

Korah

Esiashvili

Mazewski

et al. 2010

International Journal of Radiation Oncology*Biology*Physics

111

View full text Add to dashboard Cite

“…GI toxicities are relatively common and when refractory to medication, can affect outcomes and quality of life(5, 12, 13). In this study, patients receiving p-CSI had significantly less weight loss, nausea/vomiting, and medical management of dysphagia when compared to x-CSI.…”

Section: Discussionmentioning

confidence: 99%

Proton Beam Craniospinal Irradiation Reduces Acute Toxicity for Adults With Medulloblastoma

Brown

Barney

Grosshans

et al. 2013

International Journal of Radiation Oncology*Biology*Physics

172

109

View full text Add to dashboard Cite

PURPOSE Efficacy and acute toxicity of proton craniospinal irradiation (p-CSI) were compared with conventional photon CSI (x-CSI) for adults with medulloblastoma. METHODS AND MATERIALS Forty adult medulloblastoma patients treated with x-CSI (n=21) or p-CSI (n=19) at XXXXX from 2003–2011 were retrospectively reviewed. Median CSI and total doses were 30.6 and 54 Gy, respectively. The median follow-up was 57 months (range 4–103) for x-CSI patients and 26 months (range 11–63) for p-CSI. RESULTS p-CSI patients lost less weight than x-CSI patients (1.2%, versus 5.8%; p=0.004), and less p-CSI patients had greater than 5% weight loss compared to x-CSI (16% versus 64%; p=0.004). p-CSI patients experienced less grade 2 nausea and vomiting compared to x-CSI (26% versus 71%; p=0.004). Patients treated with x-CSI were more likely to have medical management of esophagitis than p-CSI patients (57% vs 5%, p=<0.001). p-CSI patients had a smaller reduction in peripheral white blood cells (WBC), hemoglobin and platelets compared to x-CSI (WBC 46% versus 55%, p=0.04; hemoglobin 88% versus 97%, p=0.009; platelets 48% versus 65%, p=0.05). Mean vertebral doses were significantly associated with reductions in blood counts. CONCLUSIONS This report is the first analysis of clinical outcomes for adult medulloblastoma patients treated with p-CSI. Patients treated with p-CSI experienced less treatment-related morbidity including less acute gastrointestinal and hematologic toxicities.

show abstract

“…3 Recently reported overall survival rates for both children and adults are in the 60th and 70th percentiles, a significant increase from the 29% 5-year overall survival rate reported in earlier periods. 2,[4][5][6][7][8][9][10] Studies have demonstrated that medulloblastomas in adults and children are histologically and genetically different diseases. [11][12][13] Because of obvious differences in expected survival between adults and children in the general population (with adults more likely to die than children), comparing the survival profiles of children and adults with brain tumors requires a particular approach, namely, the use of relative survival.…”

Section: Introductionmentioning

confidence: 99%

Relative survival of childhood and adult medulloblastomas and primitive neuroectodermal tumors (PNETs)

Smoll

2011

Cancer

View full text Add to dashboard Cite

BACKGROUND: Medulloblastomas are 1 of the most common brain tumors in children but can affect individuals of all ages. For this report, the author investigated the impact of medulloblastomas/primitive neuroectodermal tumors (PNETs) on the US population with a focus on age differences. METHODS: Data from the Surveillance, Epidemiology, and End Results (SEER) database were used to describe cumulative relative survival (CRS) using crude, period, and longitudinal period approaches for patients diagnosed with all medulloblastoma subtypes and PNETs. CRS estimates were obtained using SEER expected mortality data and the Ederer II method for expected survival estimation. These data were applied to the construction of rational follow-up scheduling protocols. RESULTS: The 5-year period CRS for all patients who were followed between 2001 and 2006 was 69%. Adults had a worse overall prognosis, but this difference in excess hazard rates appeared only after 4 years of follow-up. Furthermore, the 5-year and 10-year CRS has improved a minimum of 11% in children, adolescents, and adults over the past 25 years. CONCLUSIONS: The survival difference between children, adolescents, and adults with medulloblastomas and PNETs depended on the length of follow-up, which was described in this report as an age-by-follow-up interaction and observed as a ''fork'' on Kaplan-Meier curves. Differences in survival between children and adults emerged only 4 years after diagnosis, and adults fared worse. There has been significant improvement in survival from medulloblastomas/PNETs since the late 1970s and early 1980s. Cancer 2012;118:1313-

show abstract

Characteristics and outcomes of medulloblastoma in adults

Cited by 46 publications

References 34 publications

Incidence, Risks, and Sequelae of Posterior Fossa Syndrome in Pediatric Medulloblastoma

Incidence, Risks, and Sequelae of Posterior Fossa Syndrome in Pediatric Medulloblastoma

Proton Beam Craniospinal Irradiation Reduces Acute Toxicity for Adults With Medulloblastoma

Relative survival of childhood and adult medulloblastomas and primitive neuroectodermal tumors (PNETs)

Contact Info

Product

Resources

About